Tarlige Mirogabalin Besilate Tablets

1. Indications and Usage
Diabetic Peripheral Neuropathic Pain:
Treatment of diabetic peripheral neuropathic pain in adults.
Postherpetic Neuralgia:
Treatment of postherpetic neuralgia in adults.
2. Dosage and Administration
Route of Administration:
For Oral Use ONLY.
Recommended Dosage:
Initiation: 5 mg taken orally twice daily.
Titration: The dose may be increased gradually (e.g., to 10 mg twice daily, then 15 mg twice daily) at intervals of at least one week based on efficacy and tolerability.
Maintenance: The recommended maintenance dose is typically 15 mg twice daily.
Maximum Dose: 30 mg per day (15 mg twice daily).
Renal Impairment Adjustment:
Mild Impairment: No adjustment necessary.
Moderate/Severe Impairment: Dose reduction and/or extended dosing intervals are required (e.g., starting at 5 mg once daily).
End-Stage Renal Disease (ESRD): Contraindicated or strictly limited (e.g., 5 mg once weekly after dialysis) depending on local regulations.
Administration:
Swallow tablets whole with water. Can be taken with or without food.
3. Mechanism of Action
Calcium Channel Modulation:
Mirogabalin is a novel “gabapentinoid” that binds selectively and with high affinity to the α2δ-1 subunit of voltage-gated calcium channels in the central and peripheral nervous systems.
Reducing Neurotransmitter Release:
By binding to this subunit, it inhibits the influx of calcium ions into presynaptic nerve terminals. This reduces the release of excitatory neurotransmitters (such as glutamate, norepinephrine, and substance P) involved in pain signal transmission.
Selectivity Advantage:
Unlike pregabalin, mirogabalin has a lower affinity for the α2δ-2 subunit (found in the cerebellum), which theoretically contributes to a potentially better side-effect profile regarding dizziness and sedation.
4. Safety and Warnings
Dizziness and Somnolence:
May cause dizziness, somnolence, or loss of consciousness. Patients should be cautioned against driving or operating machinery until they know how the drug affects them.
Weight Gain:
Weight gain has been observed. Patients should be monitored for weight changes, and lifestyle adjustments (diet/exercise) may be necessary.
Edema:
Peripheral edema may occur. Caution is advised in patients with heart failure.
Withdrawal Syndrome:
Sudden discontinuation may lead to withdrawal symptoms (e.g., insomnia, nausea, diarrhea, anxiety). Tapering off gradually is recommended.
Suicidal Ideation:
As with other antiepileptic/neuropathic drugs, monitor for emergence of suicidal thoughts or behavior.
5.Adverse Reactions
Most Common:
Dizziness, somnolence, headache, peripheral edema, weight gain, constipation, and dry mouth.
6.Drug Interactions
Metabolism:
Mirogabalin is not significantly metabolized by CYP450 enzymes and does not inhibit major transporters.
Clinical Significance:
No clinically significant drug-drug interactions have been observed with common medications.
Caution:
Caution is advised when used concomitantly with other CNS depressants (e.g., opioids, benzodiazepines) due to the additive risk of sedation and respiratory depression.
7.Pharmaceutical Information
Chemical Composition:
Active Ingredient: Mirogabalin Besilate.
Available Strength: 5 mg, 10 mg, 15 mg tablets.
Appearance: White to off-white, film-coated tablets.
Storage: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Keep in the original package to protect from moisture.